article thumbnail

Using EMR data to describe administrative workload of primary care providers in Nova Scotia, Canada [Secondary data analysis]

Annals of Family Medicine

Context: Primary care providers in Canada face significant workload challenges, including managing prescriptions, referrals, and laboratory tests alongside patient visits. Outcome measures: Average number of prescriptions, referrals, and laboratory tests per encounters among primary care providers in Nova Scotia from 2007 to 2022.

article thumbnail

Risking It All For a New Business Model at Family Physicians of St. Joe

Family Physicians of St. Joseph

Larger companies now dominate the healthcare landscape, yet through innovation and a dedication to exceptional patient care, Family Physicians of St. They have remained independent and committed to caring for patients as a small practice, all the while introducing new ideas and setting new standards in Michigan’s Great Southwest.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Key to Higher Case Acceptance

CDOCS

With the ability to offer better APRs to people with good credit and show patients the APRs they prequalify for with no effect on their credit score, LendingClub stands out from the rest. LendingClub Patient Solutions is one of the most trusted names in dental financing. LendingClub provides a robust suite of payment options.

Finance 52
article thumbnail

FDA Cracks Down on ClinicalTrials.gov Reporting Failures

FDA Law Blog

for failure to submit the required information following completion of a clinical trial evaluating the safety and effectiveness of the drug dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (see FDA press release announcing the Notice of Noncompliance here ). National Library of Medicine.

Clinic 52
article thumbnail

New Legislation Would Cut Off Access To The Courts And Immunize FDA Actions From Timely Judicial Review

FDA Law Blog

Subsection 505(q) initially was added by Section 914 of the 2007 FDA Amendments Act (“FDAAA”), Pub. 110-85 (2007), as amended by Section 301 of Pub. 1067 might allow these issues to be litigated months down the road therefore provides no solace: That’s far too late for patients, sponsors, and the broader public.

IT 59
article thumbnail

My 15-Year Journey With Lithium Disilicate

CDOCS

png]<br /> <em><span style="font-size:11px;">​Figure& 1:& <span data-contrast="auto" xml:lang="EN-US">A life-long bruxer, this patient presented with lost teeth in the posterior and compensatory eruption of lower anterior teeth.</span>&

article thumbnail

FDA Cracks Down on ClinicalTrials.gov Reporting Failures

FDA Law Blog

for failure to submit the required information following completion of a clinical trial evaluating the safety and effectiveness of the drug dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (see FDA press release announcing the Notice of Noncompliance here ). National Library of Medicine.

Clinic 40